Related Experiment Videos
Tissue penetration and clinical efficacy of enoxacin in urinary tract infections
1Department of Surgery, Community Health Sciences, University of Alabama, Tuscaloosa.
Abstract:
The fluoroquinolones in general, and particularly enoxacin, show great promise in the treatment of urinary tract infection. Orally administered enoxacin achieves high concentrations in the serum and urine as well as in prostate tissue, kidney and perirenal fat and muscle. These concentrations are generally in excess of the minimum inhibitory concentrations (MIC) for 95% of the common uropathogens, including Escherichia coli, Pseudomonas aeruginosa, Klebsiella spp., Proteus spp., Enterobacter spp., Serratia marcescens and Staphylococcus saprophyticus. In comparative clinical trials, treatment with oral enoxacin has achieved satisfactory clinical results (symptoms improved or absent) in 67 to 96% of patients and satisfactory bacteriological results (less than 10(4) colony count of the original bacteria) in 77 to 98% of patients. Clinical cure or improvement occurred in 94 to 100% of patients in uncontrolled trials, with corresponding satisfactory bacteriological results of 82 to 100%. In a number of studies of patients with difficult-to-treat infections, satisfactory clinical results were achieved in 92 to 100% of patients and satisfactory bacteriological results in 89 to 100% of patients.
Insights
Enoxacin, a fluoroquinolone antibiotic, effectively treats urinary tract infections by reaching high concentrations in various body tissues. Clinical trials show high success rates in symptom improvement and bacterial eradication for difficult-to-treat infections.
Area of Science:
- Pharmacology
- Urology
- Infectious Diseases
Background:
- Urinary tract infections (UTIs) are common, often caused by uropathogens like E. coli and P. aeruginosa.
- Fluoroquinolones are a class of antibiotics used to treat bacterial infections.
- Enoxacin is an oral fluoroquinolone with potential for UTI treatment.
Purpose of the Study:
- To evaluate the efficacy and pharmacokinetic profile of enoxacin in treating urinary tract infections.
- To assess enoxacin's concentration in serum, urine, and various tissues relevant to UTIs.
Main Methods:
- Pharmacokinetic analysis of orally administered enoxacin.
- Determination of enoxacin concentrations in serum, urine, prostate, kidney, and muscle tissue.
- Assessment of minimum inhibitory concentrations (MICs) against common uropathogens.
- Review of clinical trial data, including comparative and uncontrolled studies.
Main Results:
- Enoxacin achieved high concentrations in serum, urine, prostate, kidney, and muscle, exceeding MICs for 95% of common uropathogens.
- Comparative clinical trials reported satisfactory clinical results in 67-96% of patients and bacteriological results in 77-98%.
- Uncontrolled trials showed clinical cure/improvement in 94-100% and satisfactory bacteriological results in 82-100%.
Conclusions:
- Enoxacin demonstrates significant promise for treating urinary tract infections due to its favorable pharmacokinetic profile and high efficacy.
- High concentrations in key tissues and potent activity against uropathogens support enoxacin's role in UTI management.
- Enoxacin achieved high clinical and bacteriological success rates, even in difficult-to-treat infections.